Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Journal of Immunology (Baltimore, Md. : 1950)|April 5, 2022
Characterization of Altered Gene Expression and Histone Methylation in Peripheral Blood Mononuclear Cells Regulating Inflammation in COVID-19 PatientsXiaoming Yang, Alex C Rutkovsky, Juhua Zhou, et al.
The Lancet. Infectious Diseases|October 1, 2013
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trialFrançois Raffi, Hans Jaeger, Eugenia Quiros-Roldan, et al.
Open Forum Infectious Diseases|November 29, 2023
Interprofessional Education: An Innovative Approach to Increase the Human Immunodeficiency Virus WorkforceAnna K Person, Sadie J Harris, Jennifer Burdge, et al.
AIDS and Behavior|October 19, 2012
Planning for success predicts virus suppressed: results of a non-controlled, observational study of factors associated with viral suppression among HIV-positive persons following jail releaseAnne C Spaulding, Lauren C Messina, Bryan I Kim, et al.
Nature Communications|November 11, 2022
A click chemistry amplified nanopore assay for ultrasensitive quantification of HIV-1 p24 antigen in clinical samplesXiaojun Wei, Xiaoqin Wang, Zehui Zhang, et al.
The Journal of Continuing Education in the Health Professions|September 27, 2014
VISION: a regional performance improvement initiative for HIV health care providersTheodore O Bruno, Charles B Hicks, Susanna Naggie, et al.
PLOS Digital Health|April 8, 2025
Telehealth or in-person HIV care? Qualitative study findings on decision-making from people with HIV and HIV care providers in South Carolina during the COVID-19 pandemicValerie Yelverton, Salome-Joelle Gass, Daniel Amoatika, et al.
AIDS Patient Care and Stds|October 20, 2023
The Future of Telehealth in Human Immunodeficiency Virus Care: A Qualitative Study of Patient and Provider Perspectives in South CarolinaValerie Yelverton, Salome-Joelle Gass, Daniel Amoatika, et al.
The Lancet. HIV|May 10, 2019
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trialHans-Jürgen Stellbrink, José R Arribas, Jeffrey L Stephens, et al.
International Journal of Molecular Sciences|September 10, 2021
SARS-CoV-2 Impairs Dendritic Cells and Regulates DC-SIGN Gene Expression in TissuesGuoshuai Cai, Mulong Du, Yohan Bossé, et al.
Pageof 8